Bioventus Inc. (BVS) community

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.66−0.20 (-1.84%)

Close on Nov 13, 2026Market cap $896.42MP/E 13.3Yield –

Community

Notes and questions about Bioventus from other investors

No posts about BVS yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Bioventus's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BVS.

Compare: BVS vs OFIX · BVS vs AORT · BVS vs ATRC · BVS vs ANIK · BVS vs ATEC

Revenue growth3.9% · median 13.8%

Gross margin68.7% · median 70.9%

Operating margin9.7% · median -2.1%

Net margin9.8% · median -3.7%

Company	Revenue	Growth
ATEC	$839.72M	+15.3%
OFIX	$835.41M	+2.1%
ATRC	$589.80M	+13.8%
BVS	$585.64M	+3.9%
AORT	$481.88M	+14.0%
ANIK	$123.43M	+9.4%

Company

Next earnings (est.): Mar 4, 2027, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 930
Held by institutions: 71.2%
Auditor: GRANT THORNTON LLP
SEC CIK: 1665988

Advertisement
300 × 250

See a number that looks wrong?